Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

Berg, Thomas; Andreone, Pietro; Pol, Stanislas; Roberts, Stuart; Younossi, Zobair; Diago, Moisés; Lawitz, Eric J; Focaccia, Roberto; Foster, Graham R; Horban, Andrzej; Lonjon-Domanec, Isabelle; DeMasi, Ralph; Picchio, Gaston; Luo, Donghan; De Meyer, Sandra; Zeuzem, Stefan.
Liver int ; 35(2): 448-454, Feb. 2015.
Artigo Inglês | SES-SP, SES SP - Instituto de Infectologia Emílio Ribas, SES-SP | ID: biblio-1017141

Documentos relacionados

  1. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
  2. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
  3. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
  4. Direct-acting antivirals in women of reproductive age infected with hepatitis C virus.
  5. Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals.
  6. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
  7. Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
  8. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R).
  9. Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.
  10. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.